title: Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.
abstract: OBJECTIVE
  To assess the relationship between endogenous LH serum levels after GnRH analogue administration and serum P elevation on the day of hCG administration (P hCG).
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  Reproductive medicine center in a university hospital.
  
  
  METHODS
  A total of 708 patients undergoing a GnRH agonist or antagonist protocol for IVF intracytoplasmic sperm injection.
  
  
  METHODS
  Controlled ovarian stimulation.
  
  
  METHODS
  Serum P values according to GnRH analogue; correlation between serum LH measurements and P hCG values.
  
  
  RESULTS
  Serum P hCG values were significantly lower following the GnRH antagonist than agonist protocol. A positive correlation between serum P hCG and LH area under the curve or day 6 LH values was found in the GnRH agonist group and between P hCG and LH hCG levels in both GnRH analogue regimens. With multivariate analysis, P hCG values were positively correlated with serum E(2) levels on hCG administration day and with the total FSH dose in both GnRH analogue-treated groups. Additionally, the correlation between serum P hCG and LH hCG values was positive in patients treated with the GnRH agonist protocol.
  
  
  CONCLUSIONS
  The lower serum P levels on hCG administration day following the GnRH antagonist protocol are mainly explained by lower granulosa cell steroidogenic activity. The correlation with serum LH hCG values was positive in the GnRH agonist-treated group.
authors: Center for Reproductive Medicine, Jean Verdier Hospital, University Paris XIII, Paris, France. jean-noel.hugues@jvr.aphp.fr
authors: Jean-Noêl
authors: JN
authors: Hugues
authors: Emmanuelle
authors: E
authors: Massé-Laroche
authors: Jeanne
authors: J
authors: Reboul-Marty
authors: Oksana
authors: O
authors: Boîko
authors: Céline
authors: C
authors: Meynant
authors: Isabelle
authors: I
authors: Cédrin-Durnerin
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D006107:Granulosa Cells / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood*; D015999:Multivariate Analysis; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011374:Progesterone / Q000097:blood*; D012189:Retrospective Studies; D020554:Sperm Injections, Intracytoplasmic / Q000379:methods*
chemical_list: D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D007986:Luteinizing Hormone